tablets "Glentset Advance" are applied (the fixed combination of montelukast and a levotsetirizin) to reduction of the symptoms connected with seasonal and year-round allergic rhinitis and also rhinitis at patients with bronchial asthma.

Structure

One tablet, coated, contains (active ingredients):

• montelukast of sodium it is equivalent to montelukast - 10 mg;
• a levotsetirizin of dihydrochloride - 5 mg.

Excipients: lactoses monohydrate, cellulose microcrystalline, double-base phosphate of calcium waterless, sodium of a kroskarmelloz, hydroxypropyl cellulose, magnesium stearate, opadr yellow 13B52204 (gipromelloza, titan dioxide (E 171), macrogoal, iron oxide yellow (E 172), polysorbate 80, iron oxide red (E 172)).

Contraindication

Hypersensitivity to sodium montelukast, a levotsetirizin or a tsetirizin and also other components of medicine. Drug is also contraindicated at a severe form of a renal failure (clearance of creatinine <10 ml/minute); at heavy hereditary intolerance of a galactose, deficiency of enzyme of lactose or violations of digestion of glucose and a galactose.

Route of administration

For adults and children is more senior than 15 years the recommended dose - one tablet a day, in the evening, irrespective of meal. Swallow of tablets entirely, without chewing. The course of treatment makes 14 days.

Feature of application

Pregnant

Reliable and appropriate in the way of controlled clinical trials of use of this medicine to pregnant women it was not carried out. Use during pregnancy is contraindicated.

that many medicines are excreted in breast milk at women who nurse, in need of use of medicine the feeding by a breast should be stopped.

Children

use Drug to children aged from 15 years.

Drivers

No researches of influence of the fixed combination of doses of montelukast and a levotsetirizin on ability to drive the car or to work with mechanisms were conducted. Some patients can feel drowsiness, the increased fatigue and weakness at therapy levotsetiriziny. Patients should abstain from driving and from work with potentially dangerous mechanisms during the Glentset Advance medicament treatment.

Montelukast

do not have

specific recommendations about treatment of overdose of montelukast Now. It was reported about cases of sharp overdose by montelukast during post-marketing observation and at conduct of clinical trials. To number of such messages messages about overdose cases at adults and children after application of such high doses as 1000 mg enter. Data of clinical and laboratory trials were agreed with safety profile for adults and children. In the majority of the registered cases of overdose of heavy side reactions it was not observed. The most frequent undesirable reactions were coordinated with a profile of safety of montelukast and included an abdominal pain, drowsiness, thirst, a headache, vomiting and psychomotor hyperactivity. It is unknown whether montelukast by means of peritoneal dialysis or a hemodialysis is removed.

symptomatic treatment.

to

Levotsetirizin

It was reported about overdose cases levotsetiriziny. Symptoms of overdose can include drowsiness at adults, and children have at first a condition of excitement and concern with the subsequent development of drowsiness. The known specific antidote to a levotsetirizin does not exist. At overdose the symptomatic or maintenance therapy is recommended. Levotsetirizin is not brought at dialysis.

Side effects

Montelukast

Below the most frequent undesirable reactions about which it was reported within post-marketing observation.

Infection and parasitic diseases: very often (≥ 1/10) - an upper respiratory tract infection.

from digestive tract: often (from ≥ 1/100 to <1/10) - diarrhea, nausea, vomiting.

Gepatobiliarnaya system: often (from ≥ 1/100 to <1/10) - increase in serumal levels of Transaminases (ALT, nuclear heating plant).

from skin and hypodermic cellulose: often (from ≥ 1/100 to <1/10) - skin rashes.

Levotsetirizin

It was reported about such side reactions which were observed during clinical trials:

• it is frequent (from> 1/100 to <1/10) - a headache, drowsiness, dryness in a mouth, increased fatigue;
• infrequently (from ≥ 1/1000 to <1/100) - the general weakness, an abdominal pain.

to Store

at a temperature not above 30 °C, in dry, protected from light and the place, inaccessible for children.

Expiration date - 2 years.